The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element
Open accessAbstract
In certain human cancers, the expression of critical oncogenes is driven from large regulatory elements, called super-enhancers, that recruit much of the cell’s transcriptional apparatus and are defined by extensive acetylation of histone H3 lysine 27 (H3K27ac). In a subset of T-cell acute lymphoblastic leukemia (T-ALL) cases, we found that heterozygous somatic mutations are acquired that introduce binding motifs for the MYB transcription factor in a precise noncoding site, which creates a super-enhancer upstream of the TAL1 oncogene. MYB binds to this new site and recruits its H3K27 acetylase–binding partner CBP, as well as core components of a major leukemogenic transcriptional complex that contains RUNX1, GATA-3, and TAL1 itself. Additionally, most endogenous super-enhancers found in T-ALL cells are occupied by MYB and CBP, which suggests a general role for MYB in super-enhancer initiation. Thus, this study identifies a genetic mechanism responsible for the generation of oncogenic super-enhancers in malignant cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ability of AlphaGenome to simultaneously score variant effects across all modalities accurately recapitulates the mechanisms of clinically relevant variants near the TAL1 oncogene6.”
From Advancing regulatory variant effect prediction with AlphaGenome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Detailed ALT–REF predictions for an oncogenic insertion (chr. 1: 47239296: C>ACG) characterized in ref. 6. Shown are differences between AlphaGenome predictions between the ALT and REF sequences of the variant in CD34+ CMP tracks. The ALT sequence increases expression of the TAL1 gene 7.5 kb away.”
From Advancing regulatory variant effect prediction with AlphaGenome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We evaluated three groups of gain-of-function mutations affecting the TAL1 gene in T cell acute lymphoblastic leukaemia (T-ALL): a cluster of 5′ neo-enhancer mutations upstream of the TAL1 TSS6,33, an intronic single-nucleotide variant (SNV)34 and a 3′ neo-enhancer35.”
From Advancing regulatory variant effect prediction with AlphaGenome (2026) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“By contrast, the alternative sequence introduced a MYB motif at the variant position predicted to increase TAL1 expression, chromatin accessibility and H3K27ac chromatin marks (Fig. 6e), as discovered previously6.”
From Advancing regulatory variant effect prediction with AlphaGenome (2026) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Histone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
Self-citationSelective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
FIMO: scanning for occurrences of a given motif
Grant, C. E., Bailey, T. L., & Noble, W. S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr064 · Cited by 4,247
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Self-citation
Flagged first, then by citations
1 of the 46 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 805
Topoisomerase Regulation of Cancer Gene Expression
Baranello, L., Kouzine, F., & Levens, D. (2025) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-091724-010717 · Cited by 18
Liu, G., Kim, J., Nguyen, N. H., Zhou, L., & Dean, A. (2024) · Blood · doi:10.1182/blood.2023021287 · Cited by 18
3D chromatin hubs as regulatory units of identity and survival in human acute leukemia
Gambi, G., Boccalatte, F. E., Rodriguez-Hernaez, J., Lin, Z., Nadorp, B., Polyzos, A., Tan, J., Avrampou, K., Inghirami, G., Kentsis, A., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.11.040 · Cited by 18
Stem Cell Leukemia: how a TALented actor can go awry on the hematopoietic stage
Correia, N., Arcangeli, M.-L., Pflumio, F., & Barata, J. T. (2016) · Leukemia · doi:10.1038/leu.2016.169 · Cited by 18
Shin, H. Y. (2018) · Genes & Genomics · doi:10.1007/s13258-018-0768-z · Cited by 17
TAF Family Proteins and MEF2C Are Essential for Epstein-Barr Virus Super-Enhancer Activity
Wang, C., Jiang, S., Zhang, L., Li, D., Liang, J., Narita, Y., Hou, I., Zhong, Q., Gewurz, B. E., Teng, M., et al. (2019) · Journal of Virology · doi:10.1128/jvi.00513-19 · Cited by 18
Dynamic Interactions of Transcription Factors and Enhancer Reprogramming in Cancer Progression
Zboril, E. K., Yoo, H., Chen, L., & Liu, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.753051 · Cited by 19
Yoo, K. H., Hennighausen, L. G., & Shin, H. Y. (2018) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-018-9417-z · Cited by 18
Demaree, B., Delley, C. L., Vasudevan, H. N., Peretz, C. A. C., Ruff, D., Smith, C. C., & Abate, A. R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.26.967133 · Cited by 18
Brayer, K. J., Kang, H., El‐Naggar, A. K., Andreasen, S., Homøe, P., Kiss, K., Mikkelsen, L. H., Heegaard, S., Pelaez, D., Moeyersoms, A. H. M., et al. (2023) · Cancers · doi:10.3390/cancers15051390 · Cited by 18
Enhancer scanning to locate regulatory regions in genomic loci
Buckley, M. A., Gjyshi, A., Mendoza-Fandiño, G., Baskin, R., Carvalho, R. S., Carvalho, M. A., Woods, N. T., & Monteiro, Á. N. A. (2015) · Nature Protocols · doi:10.1038/nprot.2015.136 · Cited by 17
Roles of the RUNX1 Enhancer in Normal Hematopoiesis and Leukemogenesis
Liau, W., Ngoc, P. C. T., & Sanda, T. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_10 · Cited by 16
Self-citationMutSpot: detection of non-coding mutation hotspots in cancer genomes
Guo, Y. A., Chang, M. M., & Skanderup, A. J. (2020) · npj Genomic Medicine · doi:10.1038/s41525-020-0133-4 · Cited by 15
Chromatin occupancy and target genes of the haematopoietic master transcription factor MYB
Lemma, R. B., Ledsaak, M., Fuglerud, B. M., Sandve, G. K., Eskeland, R., & Gabrielsen, O. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-88516-w · Cited by 17
A Therapeutically Targetable NOTCH1–SIRT1–KAT7 Axis in T-cell Leukemia
Lancho, O., Singh, A., da Silva-Diz, V., Tottone, L., Nunes, P. R., Aleksandrova, M., Khatun, J., Luo, S., Zhao, C., Zheng, H., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0098 · Cited by 15
Geng, K., Merino, L. G., Wedemann, L., Martens, A., Sobota, M., Sanchez, Y. P., Søndergaard, J. N., White, R. J., & Kutter, C. (2022) · Genome Research · doi:10.1101/gr.276901.122 · Cited by 19
Molecular Biology of Childhood Leukemia
Alexander, T., & Mullighan, C. G. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-043020-110055 · Cited by 18
Zhang, Y., See, Y. X., Tergaonkar, V., & Fullwood, M. J. (2022) · Cells · doi:10.3390/cells11091560 · Cited by 17
Cellular liquid–liquid phase separation: Concept, functions, regulations, and detections
Che, X., Wu, J., Liu, H., Su, J., & Chen, X. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.30980 · Cited by 16
Ishov, A. M., Gurumurthy, A., & Bungert, J. (2020) · Emerging Topics in Life Sciences · doi:10.1042/etls20190160 · Cited by 17
Yarbrough, W. G., Panaccione, A., Chang, M. T., & Ivanov, S. V. (2016) · Laryngoscope Investigative Otolaryngology · doi:10.1002/lio2.22 · Cited by 19
Core regulatory circuitries in defining cancer cell identity across the malignant spectrum
Jahangiri, L., Tsaprouni, L., Trigg, R. M., Williams, J. A., Gkoutos, G. V., Turner, S. D., & Pereira, J. D. (2020) · Open Biology · doi:10.1098/rsob.200121 · Cited by 14
Mulet‐Lazaro, R., van Herk, S., Nuetzel, M., Sijs‐Szabó, A., Díaz, N., Kelly, K., Erpelinck-Verschueren, C. A. J., Schwarzfischer, L., Stanewsky, H., Ackermann, U., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49811-y · Cited by 17
Kolekar, P. S., Balagopal, V., Dong, L., Liu, Y., Foy, S. G., Tran, Q., Mulder, H. L., Huskey, A. L. W., Plyler, E. M., Liang, Z., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1063 · Cited by 17
Genomic Alterations of Non-Coding Regions Underlie Human Cancer: Lessons from T-ALL
Rivera-Reyes, A., Hayer, K. E., & Bassing, C. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.10.004 · Cited by 15
Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?
Chung, C., & Ma, H. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1977 · Cited by 16
Han, Y. J., Zhang, J., Hardeman, A., Liu, M., Karginova, O. A., Romero, R., Khramtsova, G. F., Zheng, Y., Huo, D., & Olopade, O. I. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac168 · Cited by 15
Yu, C., Wu, G., Chang, C., Jou, S., Lu, M., Lin, K., Chen, S., Wu, K., Huang, F., Cheng, C., et al. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2022.08.001 · Cited by 15
Epo reprograms the epigenome of erythroid cells
Perreault, A. A., Benton, M. L., Koury, M. J., Brandt, S. J., & Venters, B. J. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.03.004 · Cited by 18
Epigenetics in Hematological Malignancies
Cruz-Rodríguez, N., Cómbita, A. L., & Zabaleta, J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8751-1_5 · Cited by 16
The role of noncoding mutations in blood cancers
Rahman, S., & Mansour, M. R. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.041988 · Cited by 16
Self-citationCross-species oncogenomics using zebrafish models of cancer
White, R. M. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.04.006 · Cited by 17
Isoforms of the TAL1 transcription factor have different roles in hematopoiesis and cell growth
Sharma, A., Mistriel-Zerbib, S., Najar, R. A., Engal, E., Bentata, M., Taqatqa, N., Dahan, S., Cohen, K., Jaffe‐Herman, S., Geminder, O., et al. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002175 · Cited by 14
Unique and overlapping roles of NRF2 and NRF1 in transcriptional regulation
Sekine, H., & Motohashi, H. (2023) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.23-106 · Cited by 14
Transcription Factor MYB as Therapeutic Target: Current Developments
Klempnauer, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063231 · Cited by 15
Zhang, W., Li, Z., Wang, X., & Sun, T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34035 · Cited by 13
Ekstrom, T. L., Rosok, R. M., Abdelrahman, A. M., Parassiadis, C., Manjunath, M., Dittrich, M. Y., Wang, X., Kutschat, A. P., Kanakan, A., Rajput, A., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334374 · Cited by 13
Loss of Mll3 Catalytic Function Promotes Aberrant Myelopoiesis
Arcipowski, K. M., Bulic, M., Gurbuxani, S. K., & Licht, J. D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162515 · Cited by 14
Role of the CRISPR system in controlling gene transcription and monitoring cell fate (Review)
Baliou, S., Adamaki, M., Kyriakopoulos, A. M., Spandidos, D. A., Panayiotidis, M. I., Christodoulou, I., & Zoumpourlis, V. C. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8099 · Cited by 14
Oo, Z. M., Illendula, A., Grembecka, J. E., Schmidt, C., Zhou, Y., Esain, V., Kwan, W., Frost, I. M., North, T. E., Rajewski, R. A., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1410882 · Cited by 14
Ke, J., Tian, J., Mei, S., Ying, P., Yang, N., Wang, X., Zou, D., Peng, X., Yang, Y., Zhu, Y., et al. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-1116 · Cited by 14
Somatic mutations in colorectal cancer are associated with the epigenetic modifications
Lei, H., & Tao, K. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15799 · Cited by 16
Super-Enhancers in the Regulation of Gene Transcription: General Aspects and Antitumor Targets
Bruter, A. V., Rodionova, M. D., Varlamova, E. A., & Shtil, A. A. (2021) · Acta Naturae · doi:10.32607/actanaturae.11067 · Cited by 14
Discovering single nucleotide variants and indels from bulk and single-cell ATAC-seq
Massarat, A. R., Sen, A., Jaureguy, J., Tyndale, S. T., Fu, Y., Erikson, G. A., & McVicker, G. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab621 · Cited by 15
Summers, R. J., & Teachey, D. T. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.07.010 · Cited by 14
Emerging functions of DNA transposases and oncogenic mutators in childhood cancer development
Henssen, A. G., & Kentsis, A. (2018) · JCI Insight · doi:10.1172/jci.insight.123172 · Cited by 14
Sun, H., Zhang, Z., Luo, W., Liu, J., Lou, Y. J., & Xia, S. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820934130 · Cited by 14
Yang, Z., Zheng, Y., Wu, H., Xie, H., Zhao, J., Chen, Z., Li, L., Yue, X., Zhao, B., & Bian, E. (2023) · Human Genomics · doi:10.1186/s40246-023-00480-w · Cited by 13
Huang, G., Zhang, X., Xu, Y., Chen, S., Cao, Q., Liu, W., Fu, Y., Jia, Q., Shen, J., Yin, J., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04902-8 · Cited by 15
Super-enhancers: drivers of cells’ identities and cells’ debacles
Lavaud, M., Tesfaye, R. A., Lassous, L., Royer, B. B.-L., Baud’huin, M., Verrecchia, F., Lamoureux, F., Georges, S., & Ory, B. (2024) · Epigenomics · doi:10.2217/epi-2023-0409 · Cited by 15
Ji, Y., Li, B., Lin, R., Yuan, J. T., Han, Y., Du, Y., & Zhao, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06098-x · Cited by 14
Gene editing in the context of an increasingly complex genome
Blighe, K., DeDionisio, L., Christie, K. A., Chawes, B., Shareef, S., Kakouli‐Duarte, T., Chao-Shern, C., Harding, V., Kelly, R. S., Castellano, L., et al. (2018) · BMC Genomics · doi:10.1186/s12864-018-4963-8 · Cited by 13
Impact of cancer mutational signatures on transcription factor motifs in the human genome
Chan, C. W. Y., Gu, Z., Bieg, M., Eils, R., & Herrmann, C. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0525-4 · Cited by 13
Mapping and Making Sense of Noncoding Mutations in the Genome
Yang, J., & Adli, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0905 · Cited by 13
Super-enhancers for RUNX3 are required for cell proliferation in EBV-infected B cell lines
Hosoi, H., Niibori-Nambu, A., Nah, G. S. S., Bahirvani, A. G., Mok, M. M. H., Sanda, T., Kumar, A. P., Tenen, D. G., Ito, Y., Sonoki, T., et al. (2021) · Gene · doi:10.1016/j.gene.2021.145421 · Cited by 13
Self-citationYusenko, M. V., Biyanee, A., Frank, D., Köhler, L. H. F., Andersson, M. K., Khandanpour, C., Schobert, R., Stenman, G., Biersack, B., & Klempnauer, K. (2021) · Cancers · doi:10.3390/cancers14010043 · Cited by 13
Natural Products with Antitumor Potential Targeting the MYB-C/EBPβ-p300 Transcription Module
Schmidt, T. J., & Klempnauer, K. (2022) · Molecules · doi:10.3390/molecules27072077 · Cited by 13
Jaśkiewicz, K., Maleszka-Kurpiel, M., Kabza, M., Karolak, J. A., & Gajęcka, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1197054 · Cited by 13
Fang, Y., Wang, Y., Zhu, Q., Wang, J., & Li, G. (2016) · Scientific Reports · doi:10.1038/srep32476 · Cited by 12
Huang, Y. L., Koues, O. I., Zhao, J., Liu, R., Pyfrom, S., Payton, J. E., & Oltz, E. M. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.067 · Cited by 13
Epigenomic technologies for precision oncology
Weichenhan, D., Lipka, D. B., Lutsik, P., Goyal, A., & Plass, C. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.004 · Cited by 15
USP20 as a super-enhancer-regulated gene drives T-ALL progression via HIF1A deubiquitination
Xu, L., Zhang, Z.-M., Yu, J., Ji, T., Cheng, J., Fei, X., Chu, X., Tao, Y., Xu, Y., Yang, P., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.003 · Cited by 12
Inferring Potential Cancer Driving Synonymous Variants
Zeng, Z., & Bromberg, Y. (2022) · Genes · doi:10.3390/genes13050778 · Cited by 14
Edrei, Y., Levy, R., Kaye, D., Marom, A., Radlwimmer, B., & Hellman, A. (2023) · Genome biology · doi:10.1186/s13059-023-03094-6 · Cited by 12
Atak, Z. K., Imrichová, H., Svetlichnyy, D., Hulselmans, G. J., Christiaens, V., Reumers, J., Ceulemans, H., & Aerts, S. (2017) · Genome Medicine · doi:10.1186/s13073-017-0464-7 · Cited by 13
Shaw, T. I., Dong, L., Tian, L., Qian, C., Liu, Y., Ju, B., High, A. A., Kavdia, K., Pagala, V., Shaner, B., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84647-2 · Cited by 13
Self-citationMatthews, B. J., Melia, T., & Waxman, D. J. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009588 · Cited by 12
Leveraging Allele-Specific Expression for Therapeutic Response Gene Discovery in Glioblastoma
Sen, A., Prager, B. C., Zhong, C., Park, D., Zhu, Z., Gimple, R. C., Wu, Q., Bernatchez, J. A., Beck, S., Clark, A. E., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0810 · Cited by 15
Benedetto, C. D., Oh, J., Choudhery, Z., Shi, W., Valdés, G., & Betancur, P. A. (2022) · BMC Cancer · doi:10.1186/s12885-022-10157-7 · Cited by 15
Benyoucef, A., Haigh, J. J., & Brand, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1151343 · Cited by 12
Prognostication in chronic lymphocytic leukemia
Moia, R., & Gaïdano, G. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.02.002 · Cited by 14
Discovering functional sequences with RELICS, an analysis method for CRISPR screens
Fiaux, P. C., Chen, H. V., Chen, P. B., Chen, A. R., & McVicker, G. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008194 · Cited by 9
Klempnauer, K. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.01.003 · Cited by 12
Hunger, S. P., Teachey, D. T., Grupp, S. A., & Aplenc, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00093-1 · Cited by 12
Self-citationWhole genome sequencing and its applications in medical genetics
Wu, J., Wu, M., Chen, T., & Jiang, R. (2016) · Quantitative Biology · doi:10.1007/s40484-016-0067-0 · Cited by 13
Shrestha, S., Sewell, J. A., Santoso, C., Forchielli, E., Pro, S. C., Martinez, M., & Bass, J. I. F. (2019) · Genome Research · doi:10.1101/gr.248823.119 · Cited by 12
Íñiguez-Muñoz, S., Llinàs‐Arias, P., Ensenyat-Méndez, M., Bedoya-López, A. F., Orozco, J. I. J., Cortés, J., Roy, A., Forsberg‐Nilsson, K., DiNome, M. L., & Marzese, D. M. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05314-z · Cited by 11
Deregulation of enhancer structure, function, and dynamics in acute lymphoblastic leukemia
Belver, L., Alberó, R., & Ferrando, A. A. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.03.005 · Cited by 13
Deregulation of Transcriptional Enhancers in Cancer
Azad, F. M., & Atlasi, Y. (2021) · Cancers · doi:10.3390/cancers13143532 · Cited by 12
Genome-wide association study on 13 167 individuals identifies regulators of blood CD34+cell levels
Portilla, A. L. D. L., Ekdahl, L., Cafaro, C., Ali, Z., Miharada, N., Þorleifsson, G., Žemaitis, K., Arrizabalaga, A. L., Thodberg, M., Pertesi, M., et al. (2022) · Blood · doi:10.1182/blood.2021013220 · Cited by 11
Natural and Experimental Rewiring of Gene Regulatory Regions
Downes, D. J., & Hughes, J. R. (2022) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-112921-010715 · Cited by 12
Enhancer-Mediated Formation of Nuclear Transcription Initiation Domains
Gibbons, M. D., Fang, Y., Spicola, A. P., Linzer, N., Jones, S. M., Johnson, B. R., Li, L., Xie, M., & Bungert, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169290 · Cited by 12
Modi, A., López, G., Conkrite, K. L., Su, C., Leung, T. C., Ramanan, S., Manduchi, E., Johnson, M. E., Cheung, D., Gadd, S., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3186 · Cited by 12
Self-citationTargeting General Transcriptional Machinery as a Therapeutic Strategy for Adult T-Cell Leukemia
Wong, R. W. J., Ishida, T., & Sanda, T. (2018) · Molecules · doi:10.3390/molecules23051057 · Cited by 11
Self-citationTargeting transcriptional regulators for treatment of anaplastic thyroid cancer
Lee, W. K. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.58 · Cited by 11
Cai, C., Bi, D., Bick, G., Wei, Q., Liu, H., Lu, L., Zhang, X., & Qin, H. (2021) · FEBS Letters · doi:10.1002/1873-3468.14219 · Cited by 11
Fischer, A., Lersch, R., Krätzig, N. D. A., Strong, A., Friedrich, M., Weber, J., Engleitner, T., Öllinger, R., Yen, H.-Y., Kohlhofer, U., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100276 · Cited by 10
Oncogenic Enhancers in Leukemia
Mulet‐Lazaro, R., & Delwel, R. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0211 · Cited by 11
Rapid Biosensing Method for Detecting Protein–DNA Interactions
Roth, S., Ideses, D., Juven‐Gershon, T., & Danielli, A. (2022) · ACS Sensors · doi:10.1021/acssensors.1c01579 · Cited by 10
RNA helicase DHX15 exemplifies a unique dependency in acute leukemia
Guo, H., Xu, J., Xing, P., Li, Q., Wang, D., Tang, C., Palhais, B., Roels, J., Liu, J., Pan, S., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282066 · Cited by 10
Epigenomic Consequences of Coding and Noncoding Driver Mutations
Yao, X., Xing, M., Ooi, W. F., Tan, P. B. O., & Teh, B. T. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.09.002 · Cited by 10
From Reductionism to Holism: Toward a More Complete View of Development Through Genome Engineering
Delker, R. K., & Mann, R. S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_3 · Cited by 10
The Identification and Interpretation of cis-Regulatory Noncoding Mutations in Cancer
Patel, M. B., & Wang, J. (2018) · Microarrays · doi:10.3390/ht8010001 · Cited by 10
Principles and methods of integrative chromatin analysis in primary tissues and tumors
Cejas, P., & Long, H. W. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188333 · Cited by 11
The evolution of leukaemia from pre‐leukaemic and leukaemic stem cells
Shlush, L. I., & Feldman, T. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13236 · Cited by 10
Huang, P., Zhang, B., Zhao, J., & Li, M. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.827657 · Cited by 10
Aberrant activity of NKL homeobox gene NKX3-2 in a T-ALL subset
Nagel, S., Meyer, C., Kaufmann, M., Zaborski, M., MacLeod, R. A. F., & Drexler, H. G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197194 · Cited by 10
Zhu, D., Jiang, T., Ma, D.-Y., Zhang, H., Zhang, J., Lv, W.-Q., Gong, M., Wang, H., Liu, Z., Su, H.-Y., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02000-0 · Cited by 9
From Genotype to Phenotype: How Enhancers Control Gene Expression and Cell Identity in Hematopoiesis
Mulet‐Lazaro, R., & Delwel, R. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000969 · Cited by 11
He, X., Wu, D., Xiao, M., Lei, Y., Lei, Y., Yu, X., & Shi, S. (2024) · Science Advances · doi:10.1126/sciadv.adk6633 · Cited by 9
Metadata
- Authors
- Mansour, M. R., Abraham, B. J., Anders, L., Berezovskaya, A., Gutierrez, A., Durbin, A. D., Etchin, J., Lawton, L., Sallan, S. E., Silverman, L. B., Loh, M. L., Hunger, S. P., Sanda, T., Young, R. A., & Look, A. T.
- Affiliations
- Harvard University (US)
- Whitehead Institute for Biomedical Research (US)
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
- Boston Children's Hospital (US)
- University of California, San Francisco (US)
- Children's Hospital Colorado (US)
- National University of Singapore (SG)
- Corresponding author
- Abraham, Brian J.
- Anders, Lars
- Young, Richard A.
- Look, A. Thomas
- ORCID
- Venue
- Science
- Published
- 2014-12-12
- Volume
- 346
- Issue
- 6215
- Pages
- 1373-1377
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4720521
- OpenAlex
- W2082414039
- Cited by
- 801
- References
- 46
- Citations by year
- 2026: 32 · 2025: 49 · 2024: 61 · 2023: 77 · 2022: 84 · 2021: 85 · 2020: 80 · 2019: 62 · 2018: 65 · 2017: 77 · 2016: 76 · 2015: 49 · 2014: 4
- FWCI
- 28.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- UCL Discovery (University College London) (submittedVersion)
- PMC
- Funders
- National Human Genome Research Institute (R01HG002668)
- National Cancer Institute (R21CA167124, CA114766, CA30969, R01CA176746, CA‐98413, U10CA098413, U24CA114766, U10CA030969, P01CA068484, CA 29139, R01CA120215, 5P01CA68484, U10CA029139, U10CA098543, P01CA109901, CA167124, CA120215, CA-98543, P30CA014051)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- super-enhancers, T-cell acute lymphoblastic leukemia, MYB transcription factors, somatic mutations, H3K27 acetylation, CBP, RUNX1, GATA3, transcriptional regulation, oncogene expression
- MeSH terms
- T-Cell Acute Lymphocytic Leukemia Protein 1, Acetylation, Base Sequence, Binding Sites, Enhancer Elements, Genetic, Histones, Humans, Molecular Sequence Data, Mutation, Oncogenes, Proto-Oncogene Proteins, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins c-myb, DNA, Intergenic, Cell Line, Tumor, Basic Helix-Loop-Helix Proteins, Basic Helix-Loop-Helix Transcription Factors, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, INDEL Mutation, Protein Interaction Domains and Motifs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
